O- 23 STRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS

IF 3.7 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Luis Antonio Díaz , Sergio García , Rayan Khan , Gustavo Ayares , Javier Uribe , Francisco Idalsoaga , José Miguel Fuentealba , Eduardo Fuentes , Katherine Maldonado , Mariana Lazo , Catterina Ferreccio , Manuel Mendizabal , Melisa Dirchwolf , Patricia Guerra , Claudia P. Oliveira , Mario Guimarães , Mario Reis , Giada Sebastiani , Mayur Brahmania , Alnoor Ramji , Juan Pablo Arab
{"title":"O- 23 STRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS","authors":"Luis Antonio Díaz ,&nbsp;Sergio García ,&nbsp;Rayan Khan ,&nbsp;Gustavo Ayares ,&nbsp;Javier Uribe ,&nbsp;Francisco Idalsoaga ,&nbsp;José Miguel Fuentealba ,&nbsp;Eduardo Fuentes ,&nbsp;Katherine Maldonado ,&nbsp;Mariana Lazo ,&nbsp;Catterina Ferreccio ,&nbsp;Manuel Mendizabal ,&nbsp;Melisa Dirchwolf ,&nbsp;Patricia Guerra ,&nbsp;Claudia P. Oliveira ,&nbsp;Mario Guimarães ,&nbsp;Mario Reis ,&nbsp;Giada Sebastiani ,&nbsp;Mayur Brahmania ,&nbsp;Alnoor Ramji ,&nbsp;Juan Pablo Arab","doi":"10.1016/j.aohep.2023.101273","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Although the WHO strategy aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030, national strategies are variable worldwide. This study aimed to assess the establishment of different policies and strategies to eliminate HCV in the Americas.</p></div><div><h3>Materials and Methods</h3><p>We conducted a 23-item survey about HCV-related policies and strategies among gastroenterologists and hepatologists in the Americas. The survey was carried out electronically (2022–2023). Data were compared with governmental institutions, regulatory agencies, scientific societies, and scientific publications. We estimated an index obtained from a regression scoring method through exploratory analysis, and row values were normalized from 0 to 100.</p></div><div><h3>Results</h3><p>We obtained 52 responses from 19 countries. The median HCV-related policies index was 51.4 [IQR:27.3–70.1]. The lower establishment of HCV-related policies was observed in Ecuador (0.0), Honduras (6.6), and Costa Rica (9.8), while the highest performance was observed in Argentina (94.1), Colombia (94.7), and Canada (100)(Figure 1A). Fifteen (78.9%) countries have adopted a national strategic plan to eliminate HCV. Three (15.8%) countries have universal screening for HCV infection (Figure 1B). After a positive HCV serological test, 10 (52.6%) countries perform reflex testing to confirm HCV diagnosis using the same sample. However, only 7 (36.8%) countries have an alert system for the requesting physician. Twelve (63.2%) countries have a direct referral system for specialized care of HCV-positive cases. Universal access to direct-acting antivirals (DAAs) exists in 15 (78.9%) countries. Universal access to DAAs was not widely available in Cuba, Ecuador, Venezuela, and the United States. Seven (36.8%) countries have generic DAAs available. Only 3 (15.8%) countries performed a retrospective search for HCV-positive cases that could have been lost to follow-up.</p></div><div><h3>Conclusions</h3><p>Although most countries have adopted a national strategic plan to eliminate HCV, there are several issues and barriers to elimination in the Americas.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268123003769/pdfft?md5=fdccb539e43091b204418b3e3e514f13&pid=1-s2.0-S1665268123003769-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268123003769","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and Objectives

Although the WHO strategy aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030, national strategies are variable worldwide. This study aimed to assess the establishment of different policies and strategies to eliminate HCV in the Americas.

Materials and Methods

We conducted a 23-item survey about HCV-related policies and strategies among gastroenterologists and hepatologists in the Americas. The survey was carried out electronically (2022–2023). Data were compared with governmental institutions, regulatory agencies, scientific societies, and scientific publications. We estimated an index obtained from a regression scoring method through exploratory analysis, and row values were normalized from 0 to 100.

Results

We obtained 52 responses from 19 countries. The median HCV-related policies index was 51.4 [IQR:27.3–70.1]. The lower establishment of HCV-related policies was observed in Ecuador (0.0), Honduras (6.6), and Costa Rica (9.8), while the highest performance was observed in Argentina (94.1), Colombia (94.7), and Canada (100)(Figure 1A). Fifteen (78.9%) countries have adopted a national strategic plan to eliminate HCV. Three (15.8%) countries have universal screening for HCV infection (Figure 1B). After a positive HCV serological test, 10 (52.6%) countries perform reflex testing to confirm HCV diagnosis using the same sample. However, only 7 (36.8%) countries have an alert system for the requesting physician. Twelve (63.2%) countries have a direct referral system for specialized care of HCV-positive cases. Universal access to direct-acting antivirals (DAAs) exists in 15 (78.9%) countries. Universal access to DAAs was not widely available in Cuba, Ecuador, Venezuela, and the United States. Seven (36.8%) countries have generic DAAs available. Only 3 (15.8%) countries performed a retrospective search for HCV-positive cases that could have been lost to follow-up.

Conclusions

Although most countries have adopted a national strategic plan to eliminate HCV, there are several issues and barriers to elimination in the Americas.

O- 在美洲消除丙型肝炎病毒感染的 23 项战略
引言和目标尽管世界卫生组织的战略目标是到 2030 年消除丙型肝炎病毒(HCV)这一公共卫生威胁,但世界各国的战略各不相同。本研究旨在评估美洲国家为消除丙型肝炎病毒而制定的不同政策和战略。材料与方法我们对美洲国家的胃肠病学家和肝病学家进行了一项有关丙型肝炎病毒相关政策和战略的 23 个项目的调查。调查以电子方式进行(2022-2023 年)。我们将数据与政府机构、监管机构、科学协会和科学出版物进行了比较。我们通过探索性分析估算了回归评分法得出的指数,行值从 0 到 100 进行了归一化处理。HCV相关政策指数的中位数为51.4 [IQR:27.3-70.1]。厄瓜多尔(0.0)、洪都拉斯(6.6)和哥斯达黎加(9.8)的 HCV 相关政策制定率较低,而阿根廷(94.1)、哥伦比亚(94.7)和加拿大(100)的相关政策制定率最高(图 1A)。15个国家(78.9%)通过了消除丙型肝炎病毒的国家战略计划。三个国家(15.8%)普及了 HCV 感染筛查(图 1B)。HCV血清学检测呈阳性后,10个(52.6%)国家会使用同一样本进行反射检测以确诊HCV。然而,只有 7 个国家(36.8%)为提出申请的医生建立了警报系统。有 12 个国家(63.2%)建立了直接转诊系统,对 HCV 阳性病例进行专门治疗。15个(78.9%)国家普及了直接作用抗病毒药物(DAAs)。古巴、厄瓜多尔、委内瑞拉和美国尚未普及直接抗病毒药物。7个国家(36.8%)有非专利DAAs。只有 3 个国家(15.8%)对可能失去随访的 HCV 阳性病例进行了回顾性搜索。结论虽然大多数国家已通过了消除 HCV 的国家战略计划,但在美洲消除 HCV 还存在一些问题和障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of hepatology
Annals of hepatology 医学-胃肠肝病学
CiteScore
7.90
自引率
2.60%
发文量
183
审稿时长
4-8 weeks
期刊介绍: Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信